anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diabetic retinopathy (DR) is a common complication of diabetes, with its prevalence increasing globally. While previous research has linked obesity indices such as body mass index (BMI) to DR, the association with weight-adjusted-waist index (WWI) remains unclear. Additionally, the relationship between WWI and DR has not been fully elucidated. This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (2005-2008) to investigate these associations in Americans aged 40 and above. The study included 5436 participants (2705 men and 2731 women). Weighted logistic regression analysis revealed a significant increase in DR prevalence with higher WWI and BMI values. Smooth curve analysis demonstrated a linear correlation between WWI and DR. The findings suggest that both WWI and BMI are independently associated with DR risk among older US adults, highlighting the importance of considering central obesity measures in assessing diabetic complications.
1317184 Injectable anaesthetics GLAXO LABORATORIES Ltd 11 June 1970 [20 June 1969] 31371/69 Heading A5B [Also in Division C2] Anaesthetic compositions suitable for use by parenteral administration comprise an aqueous solution containing at least 1mg/ml of 3α- hydroxy-5α-pregnane-11, 20-dione and a non- ionic surface-active agent serving to solubilize the steroid. Preferably they contain at least 1% by weight of the agent and this has an HLB value of 9-18. Suitable agents include polyoxyethylated derivatives of fatty glyceride oils, polyoxyethylene ethers of long-chain alcohols, polyoxyethylene - polyoxypropylene ethers, polyoxyethylene ethers of alkyl phenols, polyoxyethylated fatty acid esters of sugar alcohol anhydrides, long-chain alkanoyl mono- and di-alkanolamides and polyethylene glycol esters of long-chain fatty acids. The solubility of the anaesthetic steroid may be further increased by addition of a steroid of the formula: wherein R is an optionally substituted alkanoyl, aroyl or aralkanoyl group. These steroids are described and claimed in Specification 1317185. They also possess some anaesthetic activity.
FIELD: biotechnology. SUBSTANCE: agriculture animal corneas are placed in a mixture of equal parts of physiological solution and distilled water at ratio to cornea tissue and an aqueous mixture 1:1, frozen three-fold at 0 C, milled to particle size 0.1 x 0.1 mm and ethanol is added to final concentration 1%. Mixture is homogenized, ethanol is added again to final concentration 5% and boiled for 5-10 min. Method provides preparing the end product at high content of sulfated glycoseaminoglycans and practically no containing protein and other inert substances. EFFECT: improved method of preparing. 1 ex
The safety and effectiveness of fluticasone propionate ointment have not been established in pediatric patients. Use of fluticasone propionate ointment in pediatric patients is not recommended.

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic effects when treated with topical drugs. They are, therefore, also at greater risk of HPA axis suppression and adrenal insufficiency upon the use of topical corticosteroids [see Warnings and Precautions (5.1)].

In a trial of 35 pediatric subjects treated with fluticasone propionate ointment, 0.005% for atopic dermatitis over at least 35% of body surface area, subnormal adrenal function was observed with cosyntropin stimulation testing at the end of 3 to 4 weeks of treatment in 4 subjects who had normal testing prior to treatment. It is not known if these subjects had recovery of adrenal function because follow-up testing was not performed. The decreased responsiveness of cosyntropin testing was not correlated to age of subject, amount of fluticasone propionate ointment used, or serum levels of fluticasone propionate.

In the above trial, telangiectasia on the face was noted in one subject on the eighth day of a 4-week treatment period. Facial use was discontinued and the telangiectasia resolved.

HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids.
Cyber-security techniques are described for monitoring a cloud environment and identifying potential problems, including malicious threats, to the monitored cloud environment using operational telemetry. Techniques are described for monitoring and collecting data related to reverse or recursive DNS (rDNS) traffic associated with a monitored cloud environment. The recursive DNS traffic includes recursive DNS (rDNS) requests originating from the cloud environment and responses to those requests received from DNS resolvers. This collected data is then analyzed to identify potential threats to the monitored cloud environment. The collected data may be analyzed to identify potential sources of threats and to identify one or more portions of the cloud environment that are the targets of the threats. The analysis may trigger alerts to be generated, actions to be performed (e.g., protective measures), reports to be generated, patterns to be recognized, etc.
The ACT + MBRP group will follow a manualized clinical protocol. Treatment will include 12 weekly, virtual group-based sessions, each lasting 90 minutes. Group sizes will range from three to ten participants. All sessions will be audio recorded for fidelity. Over the course of the group meetings, participants identify areas of meaningful functioning that have been adversely impacted by pain, learn methods to enhance pain willingness in the service of these meaningful areas, and practice present-focused awareness skills. Group sessions include discussions of the impact of pain and distress avoidance, identifying alternatives to this avoidance and establishing plans for behavior change, demonstration and role-playing exercises, and homework assignments. Participants are provided with a treatment manual to help guide and inform practice outside of group sessions.
Participants received tesevatinib 100 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
Data of a supply chain is received. The data includes components moving through a locations at points in time. Risks are identified that relate to at least some of the locations. Likelihoods of each of the risks impacting any of the components at any of the locations at any of the points of time are calculated by simulating the risks spreading across space and time. A risk of the risks is identified as having more than a threshold likelihood of impacting at least one component at a respective location at a respective point in time. A change to the supply chain that lowers a likelihood of the risk impacting the at least one component at the respective location at the respective point in time to below the threshold likelihood is provided to a user.
An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.
The invention belongs to the biotechnology and the medical field and discloses a new human epididymal specific expression sperm binding protein HEL-214 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-214 protein and provides a recombinant expression vector which carries a DNA sequence used for encoding the protein. The protein is located in a back region of the head of a mature sperm, has higher expression level in an epididymis, a testis and a liver and has lower expression level or no expression in other tissues. A band of about 15 KD is detected in the epididymis by using Western blot. The HEL-214 protein can be used as a target protein for developing an immunological contraceptive and clinically diagnosing and treating male infertility. A method for detecting a corresponding gene or protein based on development of the HEL-214 protein can be widely used for the research field of reproductive medicine.
This study is a longitudinal analysis of STD/HIV exposure among adolescent female offenders in Mississippi, a population that is disproportionately African American, and at higher risk than adolescents in general due to their propensity to engage in a variety of risk-taking behaviors, earlier onset of sexual behaviors, and the greater prevalence of mental disorders, substance abuse disorders, maltreatment, and family dysfunction. Based on social cognitive theory and Fisher and Fisher's (1992) IMB (Information, Motivation, and Behavioral skills) model, we will evaluate a drug abuse related HIV risk reduction intervention and compare outcomes against a STD/HIV information and health education control condition.

Approximately 400 females committed to the state reformatory/training school for girls will be recruited for participation. The research design will consist of alternating cohort/waves of about 50 subjects each. One treatment condition will be administered at a time with a washout period between cohort/waves. Over a three year period, one half of subjects will get 18 hours of STD/HIV prevention and one half will get 18 hours of Health Education. All subjects will receive one individual counseling session designed to enhance motivation for behavioral change just prior to release from training school. Before and after the intervention, subjects' social competency skills, condom application skills, and health knowledge will be measured. Before intervention and at 6-month and 12-month follow-up, self-report measures of alcohol and drug use, condom use, sexual risk behaviors, and measures of victimization, partner risk, condom attitudes, self-efficacy, and communication related to condom use and risk reduction will be collected. Urine tests for the detection of 2 STDs (chlamydia and gonorrhea) will also be performed at admission to Columbia Training School and at 6-month and 12-month follow-up.
Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2.
A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 µm or less, and which may be homogeneous.
505,972. Film - producing dressings. BEUTNER, R. Oct. 16, 1937, No. 28242. [Class 81 (ii)] [Also in Group IV] Therapeutic preparations for application to the skin are prepared by mixing a resinous alcohol-soluble phenol-formaldehyde condensate with a medicinal agent for the treatment of the skin and with alcohol in such proportions as to produce a composition capable of leaving, on drying, a substantially dry film. The medicinal agents that may be used are tars, salicylic acid, benzoic acid, malachite green, gentian violet and other medicinal dyes, iodine, metaphen, mercuro chrome and other mercurial disinfectants, camphor and related compounds, hydroxyquinoline, ethyl aminobenzoate, orthoform, resorcinol, hexyl resorcinol; hiberylin and other resorcinol derivatives, thymol, guaiacol, eugenol, stearoptens and volatile oils, silver nitrate and bichloride of mercury.
INTRODUCTION: Gestational diabetes mellitus (GDM) can adversely impact pregnancy outcomes. LGA is a common complication of GDM. Telemedicine is increasingly used for the follow-up of chronic diseases. The objective of this study was to evaluate if implementing a telemedicine solution for GDM could decrease the frequency of large for gestational age (LGA) newborns in a rural hospital.
METHODS: This retrospective interrupted-time-series study was conducted in a rural French hospital. An LGA newborn was defined as a newborn with weight ≥ 90th percentile. The intervention period was defined as starting 45 days after the initial introduction of the telemedicine solution. The two timeframes were: 1 January 2015 to 28 April 2017 (baseline period) and 12 June 2017 to 31 December 2021 (intervention period).
RESULTS: Between 2015 and 2021, 14,382 single births were registered in the hospital and 1,981 births from women with GDM were included. The mean age of mothers was 31.71 ± 5.54 and 32.30 ± 5.14 in women with newborns with birthweights lower and higher than the 90th percentile respectively (p=0.09). LGA births were reduced from 76/533 (14.3%) in the baseline period to 170/1,448 (11.7%) in the intervention period. This reduction became statistically significant in the multivariate analysis (protective OR: 0.541, 95%CI [0.311 to 0.930],p=0.13). Obesity was associated with LGA (OR: 1.877, 95%CI [1.394 to 2.558]).
CONCLUSIONS: The implementation of a telemedicine solution for GDM care in a rural general hospital was associated with a decrease in the adjusted odds of LGA births.
Psoriasis is a chronic inflammatory skin disease. It is believed to be caused by an overactive immune system that speeds the growth of skin cells. This abnormal skin growth results in patches of inflamed skin, which can itch, crack, and bleed. Cyclosporine is an immunosuppressant drug that is used in more severe cases of psoriasis to slow down the growth of skin cells. However, cyclosporine use is associated with several side effects, including kidney damage, high blood pressure, and skin sensitivity. This study will evaluate whether lower doses of cyclosporine can cause fewer side effects and still produce the same beneficial results that are seen with the standard administration of cyclosporine.

Participants in this study will receive treatment with cyclosporine for up to 30 weeks. Study visits will occur every 2 weeks and will include a physical exam, a psoriasis symptom evaluation, blood collection, and various questionnaires on quality-of-life issues. Participants will be followed for 2 years.
The present invention discloses the application of alginic polysaccharide sulfate in the preparation of medicines for treating renal failure. The alginic polysaccharide sulfate is a product between cells of brown algae and is a pure natural product. The Shenhaikang capsule using the alginic polysaccharide sulfate as raw materials is mainly used for treating renal failure and has obvious curative effect. More than 20 technical steps of soaking algae, filtering the algae 5 times, extracting the algae twice with ethanol, washing the algae once with ethanol, regulating the gradient range of the pH value by cooperation, etc. are carried out, and then the alginic polysaccharide sulfate as a new marine medicine with favorable yield and high quality is finely prepared. The method has the advantages of mild reaction condition, less consumed raw material, low cost and suitability for batch production and comprehensive utilization of raw materials.
ExRx#2 uses the heat map image published in the 2018 Physical Activity Guidelines Advisory Committee Scientific Report that communicates the dose-response relationship between increased physical activity and improved health to prescribe the message that all physical activity across all Frequencies, Intensities, Time bouts and Types (FITT) counts towards health. ExRx#2 is founded in the Integrated Behavior Change Theory and emphasizes that all physical activity matters regardless of FITT as depicted by the heat map image. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the ExRx#2 heat map ultimate weekly goal of moving more throughout the day across all intensities in order to achieve optimal health as represented by the deep green color on the bottom right of the heat map image.
Plaque accumulation on tooth and gingival surfaces is a causative factor for oral diseases such as demineralization, dental caries, gingivitis, and periodontitis. 1 Thus, the maintenance of an adequate level of plaque control by the individual through his or her daily oral hygiene is vital to prevent and control periodontal disease which can result in tooth mobility and tooth loss. 2 Tooth brushing and flossing have been the cornerstone of oral hygiene and health.2 However, the high incidence and prevalence of gum problems in both the developed and developing countries show these mechanical routines are not enough. 1 Studies demonstrate that poor oral hygiene is widespread with about 60% of plaque found on the surfaces of the teeth after brushing.3 Furthermore, many patients find it difficult to comply with this daily regimen of brushing and flossing. 2 This may be due to the lack of manipulative skills, lack of motivation and compliance. 2 According to an overview of the challenges in dental public health in Malaysia by Allan Kah, he stated that only 26% of 15-19-year-old and only 5% of 35-44-year-olds have been reported to have healthy periodontal tissues. 4 Studies such as the one done by Deliargyris, showed that periodontal disease was associated with the enhanced systemic inflammatory response with various mediators. Thus, it may contribute to systemic diseases. For example, periodontal disease has been linked to atherosclerosis via an increased level of serum C-reactive protein, a marker for inflammation and a high-risk factor for coronary artery disease.5 Hence, there is a need to increase education and improve brushing technique. This can be done by improving oral hygiene products by incorporating a plaque disclosing dye in the toothpaste.1 The ability to see plaque while brushing will enhance patient's awareness and encourage them to be more thorough when performing oral hygiene. 1 Previous studies done by the Department of Orthodontics, University of Illinois have shown that using a toothpaste with a plaque indicating dye such as PlaqueHD® to disclose plaque while brushing resulted in more than four times as much plaque elimination between visits (51.3% reduction, p = 0.015) than participants using only the placebo toothpaste (8.3% reduction, p=0.189). 1 However, one of the limitations of the product used in that study is the high cost of the toothpaste and the difficulty in obtaining the toothpaste in South East Asia.Hence, the present study aims to assess the efficacy of a plaque disclosing toothpaste that is easily available and affordable which was developed with the Health Promotion Board of Singapore, named Shoplaq® in reducing dental plaque.
Electrical storms (ESs) following percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) patients pose a significant challenge, affecting prognostic outcomes and increasing mortality. This meta-analysis synthesized data from 11 studies involving 9,666 AMI patients to identify risk factors associated with ES following PCI. Our findings revealed an average ES incidence of 7.70%, with identified risk factors including low thrombolysis in myocardial infarction (TIMI) flow grades (0-1), elevated cardiac troponin I levels, persistent hypotension, reperfusion arrhythmias, the right coronary artery being the infarct-related artery, increased diameter of the infarct-related artery, renal dysfunction, elevated creatine kinase-MB, and bradycardia. Notably, the use of β-blockers was found to significantly reduce the risk of ES. The study underscores the importance of early identification and management of these risk factors in AMI patients undergoing PCI to prevent the occurrence of ES, highlighting the protective role of β-blockers. This research provides a foundation for future strategies aimed at reducing the incidence and improving the prognosis of ES in this patient population.
All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including duloxetine delayed-release capsules. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported and appeared to be reversible when duloxetine delayed-release capsules were discontinued. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations (8.5)]. Discontinuation of duloxetine delayed-release capsules should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.  
Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. More severe and/or acute cases have been associated with hallucination, syncope, seizure, coma, respiratory arrest, and death.
The safety and effectiveness of CYRAMZA in pediatric patients have not been established. 

The safety and effectiveness of CYRAMZA as a single agent were assessed but not established in a single-arm, multicenter, open-label study [NCT02564198] that included 23 pediatric patients aged 1 year to 16 years with relapsed or refractory solid tumors. The effect on open tibial growth plates in pediatric patients who received CYRAMZA has not been adequately studied; however, one patient in this study had progressive widening of distal femoral growth plate. No other new safety signals were observed in pediatric patients. The pharmacokinetics (PK) for these pediatric patients was within the range of the values previously observed in adults given the same dose per body weight.

Juvenile Animal Toxicity Data

In animal studies, effects on epiphyseal growth plates were identified. In cynomolgus monkeys, anatomical pathology revealed adverse effects on the epiphyseal growth plate (thickening and osteochondropathy) at all doses tested (5-50 mg/kg). Ramucirumab exposure at the lowest weekly dose tested in the cynomolgus monkey was 0.2 times the exposure in humans at the recommended dose of ramucirumab as a single agent.